These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29649904)

  • 41. Economic assessment on the management of chronic lymphocytic leukaemia.
    Goor KM; Schaafsma MR; Huijgens PC; van Agthoven M
    Expert Opin Pharmacother; 2005 Jun; 6(7):1179-89. PubMed ID: 15957971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
    Meunier G; Ysebaert L; Nguyen-Thi PL; Lepretre S; Quinquenel A; Dupuis J; Lemal R; Aurran T; Tomowiak C; Cymbalista F; Dilhuydy MS; Brion A; Morel P; Cazin B; Leblond V; Cartron G; Ré D; Béné MC; Michallet AS; Feugier P
    Hematol Oncol; 2017 Dec; 35(4):671-678. PubMed ID: 27878835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is the optimal initial treatment for chronic lymphocytic leukemia?
    Lin TS
    Oncology (Williston Park); 2007 Dec; 21(14):1641-9; discussion 1649-54, 1659, 1662. PubMed ID: 18247015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
    Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
    J Clin Oncol; 2017 Jan; 35(2):166-174. PubMed ID: 27870563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
    Joffe E; Goldschmidt N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Arad A; Polliack A; Herishanu Y;
    Eur J Haematol; 2018 Sep; 101(3):399-406. PubMed ID: 29949186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
    Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Advances in the treatment of chronic lymphocytic leukaemia].
    Mozas P; Delgado J
    Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?
    Hopson S; Casebeer A; Stemkowski S; Antol DD; Tao Z; Howe A; Patton J; Small A; Masaquel A
    J Med Econ; 2018 Feb; 21(2):152-162. PubMed ID: 28945163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
    Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
    Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
    Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Paquete AT; Miguel LS; Becker U; Pereira C; Pinto CG
    Appl Health Econ Health Policy; 2017 Aug; 15(4):501-512. PubMed ID: 28342061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
    Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.